Krystal Biotech (NASDAQ:KRYS) CAO Sells $3,401,750.00 in Stock

by · The Cerbat Gem

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) CAO Kathryn Romano sold 12,500 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the completion of the transaction, the chief accounting officer directly owned 19,318 shares of the company’s stock, valued at approximately $5,257,200.52. The trade was a 39.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Krystal Biotech Price Performance

Shares of KRYS traded up $1.95 during midday trading on Wednesday, hitting $272.65. The stock had a trading volume of 179,084 shares, compared to its average volume of 259,033. The firm has a market cap of $7.91 billion, a price-to-earnings ratio of 40.58 and a beta of 0.49. The company has a 50 day simple moving average of $260.24 and a two-hundred day simple moving average of $204.03. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $295.98.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on KRYS shares. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. HC Wainwright reissued a “buy” rating and set a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. The Goldman Sachs Group raised their price objective on Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a report on Friday, January 30th. Zacks Research downgraded Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $277.89.

View Our Latest Stock Analysis on Krystal Biotech

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently bought and sold shares of KRYS. Hantz Financial Services Inc. lifted its position in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after buying an additional 179 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares during the last quarter. AdvisorNet Financial Inc acquired a new stake in Krystal Biotech during the 3rd quarter valued at $30,000. Salomon & Ludwin LLC bought a new position in Krystal Biotech during the third quarter worth $33,000. Finally, First Horizon Advisors Inc. increased its holdings in shares of Krystal Biotech by 212.8% in the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

(Get Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

See Also